Department of Pathology, Brigham and Women's Hospital, 450 Brookline Ave., Dana 1539, Boston, MA 02215, USA.
Arch Pathol Lab Med. 2012 Oct;136(10):1210-6. doi: 10.5858/arpa.2012-0244-SA.
Although improvements in genomic technologies during the past decade have greatly advanced our understanding of the genomic alterations that contribute to lung cancer, and the disease has (to a degree) become a paradigm for individualized cancer treatment in solid tumors, additional challenges must be addressed before the goal of personalized cancer therapy can become a reality for lung cancer patients.
尽管过去十年中基因组技术的进步极大地促进了我们对导致肺癌的基因组改变的理解,并且该疾病(在一定程度上)已成为实体瘤个体化癌症治疗的范例,但在个性化癌症治疗的目标成为肺癌患者的现实之前,还必须解决其他挑战。